Gilead’s Truvada Trumps Combivir In Rx Market Share For Therapy Class
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Gilead Sciences' combination antiretroviral therapy Truvada (emtricitabine/tenofovir) achieved a market-leading 18.7% of total prescriptions in the nucleoside reverse transcriptase inhibitor class during the third quarter, according to Gilead